Chinook Therapeutics, Inc. (formerly Aduro) clinical trials
Acquired by Novartis, Aug 11, 2023 · source ↗
The registry lists 2 studies whose lead sponsor is Chinook Therapeutics, Inc. (formerly Aduro). 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 3, 2022.
- 2studies on the registry
- 0open to participants now
Before and after it joined Novartis
- First submitted before Chinook Therapeutics, Inc. (formerly Aduro) became part of Novartis
- 2
- First submitted after Chinook Therapeutics, Inc. (formerly Aduro) became part of Novartis
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Chinook Therapeutics, Inc. (formerly Aduro)’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 2
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Stopped early2100%
Over the years
- 116
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Chinook Therapeutics, Inc. (formerly Aduro)2 studies
Something wrong with this grouping? Tell us on the Novartis page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Novartis studies →
- Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck CancerTerminatedNCT03937141Phase 2
Sponsor listed in the registry: Chinook Therapeutics, Inc. (formerly Aduro) · First submitted before Chinook Therapeutics, Inc. (formerly Aduro) became part of Novartis
- Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT02675439Phase 1
Sponsor listed in the registry: Chinook Therapeutics, Inc. (formerly Aduro) · First submitted before Chinook Therapeutics, Inc. (formerly Aduro) became part of Novartis